Transporters and drug-drug interactions: important determinants of drug disposition and effects
- PMID: 23686349
- DOI: 10.1124/pr.113.007518
Transporters and drug-drug interactions: important determinants of drug disposition and effects
Abstract
Uptake and efflux transporters determine plasma and tissue concentrations of a broad variety of drugs. They are localized in organs such as small intestine, liver, and kidney, which are critical for drug absorption and elimination. Moreover, they can be found in important blood-tissue barriers such as the blood-brain barrier. Inhibition or induction of drug transporters by coadministered drugs can alter pharmacokinetics and pharmacodynamics of the victim drugs. This review will summarize in particular clinically observed drug-drug interactions attributable to inhibition or induction of intestinal export transporters [P-glycoprotein (P-gp), breast cancer resistance protein (BCRP)], to inhibition of hepatic uptake transporters [organic anion transporting polypeptides (OATPs)], or to inhibition of transporter-mediated [organic anion transporters (OATs), organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATEs), P-gp] renal secretion of xenobiotics. Available data on the impact of nutrition on transport processes as well as genotype-dependent, transporter-mediated drug-drug interactions will be discussed. We will also present and discuss data on the variable extent to which information on the impact of transporters on drug disposition is included in summaries of product characteristics of selected countries (SPCs). Further work is required regarding a better understanding of the role of the drug metabolism-drug transport interplay for drug-drug interactions and on the extrapolation of in vitro findings to the in vivo (human) situation.
Similar articles
-
Transporter-Mediated Drug-Drug Interactions and Their Significance.Adv Exp Med Biol. 2019;1141:241-291. doi: 10.1007/978-981-13-7647-4_5. Adv Exp Med Biol. 2019. PMID: 31571167 Review.
-
Stereoselectivity of chiral drug transport: a focus on enantiomer-transporter interaction.Drug Metab Rev. 2014 Aug;46(3):283-90. doi: 10.3109/03602532.2014.887094. Epub 2014 May 6. Drug Metab Rev. 2014. PMID: 24796860 Review.
-
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.Drug Metab Dispos. 2008 Apr;36(4):695-701. doi: 10.1124/dmd.107.018374. Epub 2008 Jan 23. Drug Metab Dispos. 2008. PMID: 18216274
-
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.Prog Neurobiol. 2005 May;76(1):22-76. doi: 10.1016/j.pneurobio.2005.04.006. Prog Neurobiol. 2005. PMID: 16011870 Review.
-
The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.Can J Clin Pharmacol. 2003 Spring;10(1):17-23. Can J Clin Pharmacol. 2003. PMID: 12687033 Review.
Cited by
-
Application of nitroxoline in urologic oncology - a review of evidence.Contemp Oncol (Pozn). 2024;28(1):1-8. doi: 10.5114/wo.2024.139584. Epub 2024 May 19. Contemp Oncol (Pozn). 2024. PMID: 38800529 Free PMC article. Review.
-
Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning.Nat Biomed Eng. 2024 Mar;8(3):278-290. doi: 10.1038/s41551-023-01128-9. Epub 2024 Feb 20. Nat Biomed Eng. 2024. PMID: 38378821
-
Gene Expression of Abcc2 and Its Regulation by Chicken Xenobiotic Receptor.Toxics. 2024 Jan 10;12(1):55. doi: 10.3390/toxics12010055. Toxics. 2024. PMID: 38251011 Free PMC article.
-
Molecular docking-based virtual screening, drug-likeness, and pharmacokinetic profiling of some anti-Salmonella typhimurium cephalosporin derivatives.J Taibah Univ Med Sci. 2023 Jun 9;18(6):1417-1431. doi: 10.1016/j.jtumed.2023.05.021. eCollection 2023 Dec. J Taibah Univ Med Sci. 2023. PMID: 38162870 Free PMC article.
-
Study Models of Drug-Drug Interactions Involving P-Glycoprotein: The Potential Benefit of P-Glycoprotein Modulation at the Kidney and Intestinal Levels.Molecules. 2023 Nov 10;28(22):7532. doi: 10.3390/molecules28227532. Molecules. 2023. PMID: 38005253 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous